Concerto HealthAI to collaborate with Pfizer in precision oncology

The collaboration will conduct new synthetic control arm and potential RWD outcomes study designs for therapeutics that are based on both pre- and post-approval.

Concerto HealthAI, a leading company that specializes in oncology-specific RWD (real-world data) and advanced AI (artificial intelligence)-enabled insight solutions, has recently announced that it has entered into a collaboration with pharmaceutical major Pfizer Inc. to advance work in precision oncology using its Eureka Health™ platform, AI models and real-world clinical EMR (Electronic Medical Record) & healthcare claims.

Sources claim that the data from clinical practices participating in the ASCO’s (American Society of Clinical Oncology) CancerLinQ® initiative and others throughout the U.S. will be used for the collaboration. Moreover, the partnership will aim on quickening the pace for actionable patient insights for Pfizer’s commercialized and investigational therapies used in the treatment of solid tumors and hematologic malignancies.

Commenting on the move, Jeff Elton, Ph.D., CEO, ConcertoHealthAI, said that the collaboration aims on finding and helping patientswho may benefit from new therapeutic combinations. He said that the company is usingits definitive real-world data, data science know-how, AI-enabled abstractionand strength in outcomes research to identify new and more accurate treatmentoptions; speed up the completion times for different outcomes studies; and refinestudy designs.

Chris Boshoff, M.D., Ph.D., CDO, Oncology, Pfizer Global Product Development, said that the company believes that RWD has tremendous potential to help find new ways to develop and use medicines to improve patient outcomes. He said that the company is pleased to work with Concerto HealthAI to advance insights and outcomes studies that may lead to a broader understanding of patients’ experience with its drugs.

As per reliable reports, the collaboration will conduct new synthetic control arm and potential RWD outcomes study designs for medications that are both pre- and post-approval stages. The first outcomes research and publications are expected to be available in early 2020.